![Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial - The Lancet Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/2c5962f0-7ed4-4eb8-8114-559265448c37/gr1.gif)
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial - The Lancet
![Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease | Scientific Reports Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-67026-1/MediaObjects/41598_2020_67026_Fig1_HTML.png)
Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease | Scientific Reports
![Allopurinol Initiation and Change in Blood Pressure in Older Adults With Hypertension | Hypertension Allopurinol Initiation and Change in Blood Pressure in Older Adults With Hypertension | Hypertension](https://www.ahajournals.org/cms/asset/aade3d38-3dd8-44e7-83c0-72e65c8d125f/1102fig01.jpeg)